UK cuts average commercial trial set-up to 100 days and hits its 150-day target

The Department of Health and Social Care said on 21 October 2026 that the average set-up time for commercial clinical trials in the UK fell to 100 days in the 3 months to March, from 153 days in the same period a year earlier ¹. All 24 commercial trials in that window were set up within 150 days, against a goal of 95% in the Life Sciences Sector Plan ¹.

What the data show

The government describes the change as a 35% cut in delivery times ¹. The approval stage is also running faster: every study that received combined MHRA and research ethics committee approval in September 2026 got it within 60 days, according to the department ¹. It cited the BEATRIX study, which offers pregnant women a group B streptococcus vaccine, as one trial that went from research to delivery in under 150 days, and the CHILL study, which screened its first participant 113 days after entering set-up ¹. Moderna's Nova 301 study enrolled 2,500 volunteers in 9 weeks ¹.

Sponsors quoted in the release gave their own examples. Vertex said a recent UK study activated sites in 112 days against a planned 120, and that it has worked with the NIHR Industry Hub since its launch early in 2026 ¹. The Shelford Group of ten large trusts said its members are delivering more than a third of the UK's global and European research firsts and have adopted shared set-up tools ¹.

What it means for the market

For NHS trusts, the number matters because set-up speed is one of the main things global sponsors weigh when deciding where to place studies. The government links the result to more than £3 billion in new public-private investment attracted in the first year of the sector plan ¹. The infrastructure behind it is a mix of national routes and money: the NIHR Industry Hub as a single entry point for sponsors, a network of commercial research delivery centres, and investment from the VPAG medicines pricing scheme into research delivery capacity ¹.

Data is the next lever. The Health Data Research Service, backed by up to £600 million from government and the Wellcome Trust, is meant to bring NHS and research data from across the UK into one secure system so researchers can find eligible patients and recruit faster ¹. The department also announced a cancer trials accelerator intended to make the NHS the "first-choice partner for cancer clinical trials" ¹. For suppliers of trial recruitment, feasibility and data tools, that points to demand shifting from single sites to national services, though the release gives no procurement detail.

Industry's response was supportive but conditional. Richard Torbett, chief executive of the ABPI, said gains at the first site must be repeated "across every subsequent site" and turn into more patients joining trials, and he pointed to "consecutive years of declining recruitment" ¹. GSK's Phillippa Brown called for resources and financial incentives for NHS sites to recruit more patients ¹.

The figures cover first-site set-up and approval times rather than recruitment or whole-study delivery, which the department itself names as the wider goal ¹. The headline set-up figure rests on a 3-month window and 24 commercial trials. The release is the government's own account, and it gives no independent evaluation. The stated ambition, endorsed by the ABPI, is to double trial recruitment and then double it again ¹.